This post first appeared on SEC Filings – Market Exclusive

PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On July 30, 2019, we issued a press release disclosing our joint venture agreement with New Earth Development, RushNet Inc., and XYZ Hemp, Inc.
In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including the exhibits hereto, shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
Section 9 – Financial Statements and Exhibits
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits

PREMIER BIOMEDICAL INC Exhibit
EX-99.1 2 biei_ex991.htm PRESS RELEASE Blueprint   Exhibit 99.1   Premier Biomedical Signs Joint Venture Agreement With New Earth Development,…
To view the full exhibit click here

About PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI)

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically focusing the treatment of Cancer, Multiple Sclerosis (MS), Neuropathic Pain, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig’s Disease), Fibromyalgia, Traumatic Brain Injury (TBI), Alzheimer’s disease (AD), and Blood Sepsis and Viremia. The Company intends to develop its Sequential-Dialysis Technique, to target Cancer, Alzheimer’s disease, ALS, Blood Sepsis, Leukemia and other life-threatening cancers. The Sequential-Dialysis Technique is a methodology for the removal of those molecules, which are harmful and responsible for causing diseases. Its Sequential-Dialysis Technique method removes those excitatory neural transmitters that cause the death of those cells. It also intends to develop Feldetrex, a candidate drug, for the treatment of MS, Fibromyalgia and TBI. Feldetrex utilizes a low dosage of Naltrexone to increase endogenous enkephalins10.

The post PREMIER BIOMEDICAL, INC. (OTCMKTS:BIEI) Files An 8-K Regulation FD Disclosure appeared first on Market Exclusive.

--
Copyright in text and images in this article belong to the original source.

This post first appeared on SEC Filings – Market Exclusive